In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cytochroma Inc.

Latest From Cytochroma Inc.

The Frost Factor: An M&A Leader's Standout Strategy For Opko Health

With CEO leadership in the biopharma industry more short-cycled than ever, billionaire entrepreneur Phillip Frost ranks as a competitor for the long game – the last man standing in an endurance test spanning four decades of exposure to every iteration of a fast-changing business model. Frost’s strategy at Opko eschews the approach of most of his CEO peers to seek therapeutic dominance in a narrow band of core competencies.

Business Strategies Deals

FDA Hold-Up: Opko Scrambles To Fix Problems At Manufacturing Site

Contract manufacturer Catalent Pharma is under the gun to prepare an action plan after FDA’s complete response letter on vitamin D drug Rayaldee (calcifediol).

Clinical Trials Regulation

Keeping Track: Submissions By Insys, Elusys, Opko and Bio Products; Immuno-Oncology User Fee Goals; A Genzyme 'Breakthrough'

The latest drug development news and highlights from our FDA Performance Tracker.

BioPharmaceutical Regulation

Amgen competitor Opko plans year-end NDA for Rayaldee

Opko Health will submit a new drug application (NDA) to the US FDA for Rayaldee (CTAP101) based on a second set of positive Phase III results in the treatment of secondary hyperparathyroidism (SHPT) in patients with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency.

Cardiovascular Metabolic Disorders
See All

Company Information